Moko Social Media rises after IPO prices at $8.3M

Associated Press |

NEW YORK (AP) — Shares of Moko Social Media rose Friday after the Australian company's U.S. initial public offering priced at $8.3 million.

The IPO of 1.1 million American Depositary Shares priced at $7.50 each. That was below the company's expectations.

The stock gained 10 cents, or 1.3 percent, to $7.60 in midday trading. It is trading on the Nasdaq Global Market under the ticker symbol "MOKO."

Moko Social Media Ltd. runs a U.S. social media mobile ad network and an Australian flash sale site for limited-time sales. The company plans to use the proceeds of its IPO to hire new technology staff in Australia and sales and marketing workers in the U.S., and it will buy servers and other IT infrastructure.

The underwriters of the offering will have an option to buy another 165,000 U.S. shares.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
TBACQ Tandy Brands Accessories Inc. 0.00 0.00 0.00 0

Comments


Watchlist

Symbol Last Price Change % Change
AAPL

     
AMZN

     
HD

     
JPM

     
IBM

     
BA

     
WMT

     
DIS

     
XOM

     

Can the Media Solve the Partisan Conflict?

Andrew McCarthy, Contributing Editor, The National Review; Michael Zeldin, CNN Legal Analyst; Celeste Katz, Senior Political Reporter, Glamour; Silvia Davi, SVP, Contributing Editor, Equities.com; and Doug Simon, CEO, D S Simon Media discuss how the media’s role has shaped the landscape for communicators and what the media is trying to do to reduce discord in society.

Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.